A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Phase 1
- Conditions
- Locally Advanced Solid TumorMetastatic Solid TumorHematologic Malignancies
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
- Target Recruit Count
- 164
- Registration Number
- NCT05028478
A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies
Phase 1
Terminated
- Conditions
- Relapsed Lymphoid MalignanciesRefractory Lymphoid Malignancies
- Interventions
- Drug: CN1, 0.5mg/kg and CN401, 400mgDrug: CN1, 1mg/kg and CN401, 800mgDrug: CN1, 10mg/kg and CN401, 800mgDrug: CN1, 1mg/kg and CN401, 600mgDrug: CN1, 3mg/kg and CN401, 800mg
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
- Target Recruit Count
- 7
- Registration Number
- NCT04880564
- Locations
- 🇦🇺
Monash Health - Monash Medical Centre, Bentleigh, Victoria, Australia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT04418141
- Locations
- 🇦🇹
Mater Medical Centre, Brisbane, Queensland, Austria
© Copyright 2025. All Rights Reserved by MedPath